NOTCH1 and non-small cell lung carcinoma: The in vitro and in vivo results with NY-2 against NSCLC have shown for the first time that NY-2 can inhibit the occurrence and development of NSCLC by suppressing the activation of Notch1 and Intergrinβ1 and blocking the EMT.